-- Bukwang Pharmaceutical (KRX:003000) posted first-quarter net income attributable to shareholders of 1.2 billion won, reversing the attributable net loss of 69 million won a year earlier, according to a Tuesday filing with the Korea Exchange.
Sales of the South Korean pharmaceutical company were down 0.1% year over year to 47.8 billion won.
Shares of Bukwang Pharmaceutical fell nearly 7% at market close.
Abundate (SGX:570) booked a loss of SG$320,000 in the fiscal second half ended Feb. 28, from a profit of SG$134,000 a year earlier, according to a Wednesday filing with the Singapore Exchange.Loss per share stood at SG$0.0031 compared with earnings per share of SG$0.0013 in the year-ago period.Revenue rose 6% year over year to SG$4.1 million from SG$3.9 million, backed by strong demand for local construction activities.